Study to investigate the prevalence of human papillomavirus in Barrett's oesophagus using a novel screening methodology

BMJ Open Gastroenterol. 2022 Apr;9(1):e000840. doi: 10.1136/bmjgast-2021-000840.

Abstract

Introduction: Human papillomavirus (HPV) is strongly associated with Barrett's dysplasia and oesophageal cancer suggesting a role in carcinogenesis. HPV persistence predicts treatment failure after endotherapy for Barrett's dysplasia. This pilot study applies a novel HPV screening tool (previously only used in the oropharynx) to detect HPV DNA directly and determine the prevalence rates in Barrett's oesophagus (BO).

Method: DNA was extracted from 20 formalin-fixed BO samples. HPV DNA was detected using real-time PCR and gel electrophoresis.

Results: 5 out of 20 patients were identified as positive for HPV. Prevalence was 25% in patients with BO.

Conclusion: This method can be used in BO's tissue to determine HPV infection. Adoption of this as a screening test could potentially revolutionise future research in this area. If a clear link between HPV and Barrett's dysplasia can be confirmed, this qPCR method has the potential to aid in monitoring and/or dysplasia detection by stratifying those most at risk and aid in the development of new therapies.

Keywords: Barrett's oesophagus; oesophageal cancer; polymerase chain reaction.

MeSH terms

  • Alphapapillomavirus*
  • Barrett Esophagus* / diagnosis
  • Barrett Esophagus* / epidemiology
  • Humans
  • Papillomaviridae / genetics
  • Pilot Projects
  • Prevalence